Supporting diagnosis of Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Roche provides innovative diagnostic tests and solutions to help assess risk, identify disease, and monitor patients, with specific solutions intended to meet the unique needs of women throughout the different stages of life. Roche Diagnostics has already tested over 75 million women globally.(1)

With fertility issues affecting one in six couples, Anti-Mullerian Hormone (AMH) can be an accurate marker of a woman's ovarian reserve.(2) The Roche Elecsys AMH test is a simple blood test that can be quickly performed in the laboratory to accurately deliver clear and reliable measures of a woman's AMH levels.

The Elecsys AMH assay is included on the Australian Register of Therapeutic Goods (ARTG) as an assay indicated to aid in the diagnosis of Polyendocrine Metabolic Ovarian Syndrome (PMOS) previously Polycystic Ovary Syndrome (PCOS), providing an equivalent alternative to the traditional PMOS diagnosis method of transvaginal ultrasound (TVUS).

Review PCOS Guidelines/PMOS Guidelines

Access trusted, evidence-based resources to support conversations with patients about Polyendocrine Metabolic Ovarian Syndrome (PMOS), previously known as Polycystic Ovary Syndrome (PCOS). These resources provide information that can complement clinical care and help patients better understand PMOS, its diagnosis, management and potential long-term health implications.

References:

1. Roche Diagnostics Ltd. Data on file.

2. Retrieved from: https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility Accessed 13 August 2026.